HENRY SCHEIN
NEWS RELEASE
Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747
FOR IMMEDIATE RELEASE
HENRY SCHEIN REPORTS FOURTH QUARTER RESULTS
EPS from continuing operations increases 8% to $0.90,
excluding restructuring costs
Company revises 2009 guidance
MELVILLE, N.Y. (February 24, 2009) - Henry Schein, Inc. (NASDAQ: HSIC), the
largest provider of healthcare products and services to office-based
practitioners in the combined North American and European markets, today
reported financial results for the quarter and year ended December 27, 2008.
Net sales for the fourth quarter of 2008 were $1.6 billion, a decrease
of 7.5% compared with the fourth quarter of 2007. This consists of a 1.8%
decline in local currencies (3.0% decline in internal net sales and 1.2% growth
from acquisitions) and a 5.7% decline related to foreign currency exchange (see
Exhibit A for details of sales growth). The Company previously announced an
initiative of reducing sales of certain lower-margin pharmaceutical products.
Excluding sales of those products, internal net sales in local currencies
declined 1.1%.
Income from continuing operations for the fourth quarter of 2008 was
$64.2 million, or $0.72 per diluted share. These results include certain
restructuring costs (discussed below) of $23.2 million (or $0.18 per diluted
share, after-tax) related to the elimination of approximately 300 positions from
operations and the closing of several smaller facilities. Excluding the impact
of these restructuring costs, income from continuing operations for the quarter
was $80.2 million, or $0.90 per diluted share, an increase of 4.5% and 8.4%,
respectively, compared with the fourth quarter of 2007 (see Exhibit B for
reconciliation of GAAP net income and EPS to non-GAAP adjusted net income and
EPS). The Company recorded a loss on discontinued operations during the fourth
quarter of 2008 of $7.3 million (or $0.08 per diluted share, after-tax) related
to the previously announced decision to exit its wholesale ultrasound business.
"Although internal net sales declined slightly during the fourth
quarter, we are pleased to report that excluding restructuring costs, we had
solid operating margin expansion and 8% growth in diluted EPS from continuing
operations," said Stanley M. Bergman, Chairman and Chief Executive Officer of
Henry Schein. "Operating margin for the quarter, excluding restructuring
charges, reached 8.1%, which is up 76 basis points compared with the prior year
fourth quarter.
1
-more-
For the year our operating margin, excluding restructuring charges, was 6.9%,
which is up 35 basis points and is in line with our stated Company goal for
annual operating margin expansion."
Dental Group sales of $665 million declined 2.4%, consisting of a 0.3%
decline in local currencies (all internal) and a 2.1% decline related to foreign
currency exchange. The 0.3% internal decline in local currencies consists of a
Dental consumable merchandise sales increase of 1.4% and a Dental equipment
sales and service revenues decline of 3.6%.
"Our fourth quarter Dental Group results reflect the current economic
environment and uncertainty, particularly impacting overall demand for dental
equipment," commented Mr. Bergman.
Medical Group sales of $349 million declined 12.6%, consisting of a
13.5% decline in internally generated sales and 0.9% growth due to acquisitions.
Excluding sales of certain lower-margin pharmaceutical products, noted above,
internal Medical Group sales declined approximately 6% and declined
approximately 1% when also excluding sales of influenza vaccine. Fourth quarter
Medical Group sales growth was negatively impacted by the timing of influenza
vaccine sales compared to prior year.
"During the fourth quarter we sold 3.1 million doses of influenza
vaccine. For the year we sold 13.6 million doses, which is at the midpoint of
our guidance range," said Mr. Bergman. "We are also pleased with the results
from our animal health business. Sales to our veterinary customers represented
about 14% of the Medical Group's fourth quarter total sales and were up
approximately 4.3%."
For the quarter, International Group sales of $528 million declined
10.8%, consisting of 2.9% growth in local currencies (0.1% internally generated
and 2.8% from acquisitions) and a 13.7% decline related to foreign currency
exchange.
"Results in our International Group reflect a strengthening of the U.S.
dollar," added Mr. Bergman. "Yet we are pleased to report solid internal sales
growth in most of our major markets, with double-digit internal sales gains in
local currencies reported in Australia and New Zealand."
Technology and Value-Added Services Group sales of $42 million
increased 6.5% during the quarter, consisting of 10.9% growth in local
currencies (all internally generated) and a 4.4% decline related to foreign
currency exchange.
"During the quarter we saw continued strong growth in financial
services as equipment and practice financing transactions posted 10.4% growth,
which follows 30% growth reported in the previous quarter. Our electronic
services business also was strong during the quarter," stated Mr. Bergman.
2
-more-
Full Year Results
For the 2008 full year, net sales of $6.4 billion represent an increase
of 8.3% compared with 2007. This increase consists of 7.5% local currency
growth (1.3% internally generated and 6.2% from acquisitions) and 0.8% related
to foreign currency exchange. Excluding sales of certain lower-margin
pharmaceutical products, noted above, internal net sales growth in local
currencies was 3.6%.
Income from continuing operations for 2008 was $251.0 million, or $2.75
per diluted share. Excluding the charge in the third quarter of 2008 related to
the Lehman Brothers bankruptcy ($0.03 per diluted share, after-tax) and the
fourth quarter restructuring costs, income from continuing operations for 2008
was $270.0 million, or $2.96 per diluted share, reflecting growth of 14.4% and
14.3%, respectively, compared with 2007.
Stock Repurchase Plan
Henry Schein repurchased 568,410 shares of common stock during the
fourth quarter of 2008 for a total purchase price of approximately $28 million.
The impact of this share repurchase was immaterial to fourth quarter diluted
EPS. During 2008 the Company repurchased 1,621,710 shares of common stock for a
total purchase price of approximately $83 million. Approximately $58 million
remains authorized for future common stock repurchases.
Restructuring Costs
In November 2008 Henry Schein announced plans to eliminate
approximately 300 positions from its operations around the world and to close
several smaller facilities. This initiative is substantially complete. The
Company recorded costs associated with this initiative of $23.2 million in the
fourth quarter of 2008, and expects to record remaining costs of $1 million to
$3 million in the first quarter of 2009. Annual pretax cost savings from this
initiative are expected to be approximately $24 million to $27 million and are
included in our 2009 EPS guidance.
2009 EPS Guidance
"We are revising our full-year 2009 financial guidance due to worsening
economic conditions, our expectation for continued economic weakness and the
strengthening of the U.S. dollar," commented Mr. Bergman. Henry Schein's 2009
financial guidance now is as follows:
o 2009 diluted EPS is expected to be $3.11 to $3.26, representing growth
of 5% to 10% compared with reported 2008 results, excluding charges
related to the Lehman Brothers
3
- more -
bankruptcy, as well as restructuring costs. This compares with
previous guidance for 2009 diluted EPS of $3.27 to $3.36. The 2009
guidance does not include any restructuring costs expected to be
recorded during the year.
o For the first quarter of 2009, the Company expects diluted EPS to be in
the range of flat to growth in the low-single-digit percentages,
compared with the first quarter of 2008, excluding restructuring costs
expected to be recorded during the quarter, as described above.
o 2009 diluted EPS guidance is for current continuing operations
including completed or previously announced acquisitions, and does not
include the impact of potential future acquisitions, if any.
Fourth Quarter Conference Call Webcast
The Company will hold a conference call to discuss fourth quarter
financial results today, beginning at 10:00 a.m. Eastern Standard Time.
Individual investors are invited to listen to the conference call over the
Internet through Henry Schein's Web site at www.henryschein.com. In addition, a
replay will be available beginning shortly after the call has ended.
About Henry Schein
Henry Schein, a Fortune 500(R) company and a member of the NASDAQ
100(R) Index, is recognized for its excellent customer service and highly
competitive prices. The Company's four business groups - Dental, Medical,
International and Technology - serve more than 575,000 customers worldwide,
including dental practitioners and laboratories, physician practices and animal
health clinics, as well as government and other institutions.
The Company operates through a centralized and automated distribution
network, which provides customers in more than 200 countries with a
comprehensive selection of more than 90,000 national and Henry Schein private-
brand products in stock, as well as more than 100,000 additional products
available as special-order items.
Henry Schein also offers a wide range of innovative value-added
practice solutions for healthcare professionals, such as ArubA(R), the Company's
electronic catalog and ordering system. Its leading practice-management software
solutions have an active user base of more than 60,000 practices, including
DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental practices,
MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.
4
- more -
Headquartered in Melville, N.Y., Henry Schein employs over 12,500
people and has operations or affiliates in 23 countries. The Company's net
sales reached a record $6.4 billion in 2008. For more information, visit the
Henry Schein Web site at www.henryschein.com.
In accordance with the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995, we provide the following cautionary remarks
regarding important factors that, among others, could cause future results to
differ materially from the forward-looking statements, expectations and
assumptions expressed or implied herein. All forward-looking statements made by
us are subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance
and achievements or industry results to be materially different from any future
results, performance or achievements expressed or implied by such forward-
looking statements. These statements are identified by the use of such terms as
"may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast,"
"project," "anticipate" or other comparable terms. A full discussion of our
operations and financial condition, including factors that may affect our
business and future prospects, is contained in documents we have filed with the
SEC and will be contained in all subsequent periodic filings we make with the
SEC. These documents identify in detail important risk factors that could cause
our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ
materially from current and historical results include, but are not limited to:
decreased customer demand and changes in vendor credit terms; disruptions in
financial markets; general economic conditions; competitive factors; changes in
the healthcare industry; changes in regulatory requirements that affect us;
risks associated with our international operations; fluctuations in quarterly
earnings; our dependence on third parties for the manufacture and supply of our
products; transitional challenges associated with acquisitions, including the
failure to achieve anticipated synergies; financial risks associated with
acquisitions; regulatory and litigation risks; the dependence on our continued
product development, technical support and successful marketing in the
technology segment; our dependence upon sales personnel and key customers; our
dependence on our senior management; possible increases in the cost of shipping
our products or other service issues with our third-party shippers; risks from
rapid technological change; risks from potential increases in variable interest
rates; possible volatility of the market price of our common stock; certain
provisions in our governing documents that may discourage third-party
acquisitions of us; and changes in tax legislation that affect us. The order in
which these factors appear should not be construed to indicate their relative
importance or priority.
We caution that these factors may not be exhaustive and that many of these
factors are beyond our ability to control or predict. Accordingly, any forward-
looking statements contained herein should not be relied upon as a prediction of
actual results. We undertake no duty and have no obligation to update forward-
looking statements.
(TABLES TO FOLLOW)
5
- more -
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
Three Months Ended Years Ended
----------------------------- -----------------------------
December 27, December 29, December 27, December 29,
2008 2007 2008 2007
------------- ------------- ------------- -------------
(unaudited) (unaudited)
Net sales .................................................... $ 1,584,653 $ 1,712,836 $ 6,394,874 $ 5,904,416
Cost of sales ................................................ 1,116,987 1,229,143 4,510,336 4,187,842
------------- ------------- ------------- -------------
Gross profit .......................................... 467,666 483,693 1,884,538 1,716,574
Operating expenses:
Selling, general and administrative ...................... 339,580 358,251 1,441,695 1,328,635
Restructuring costs ...................................... 23,240 -- 23,240 --
------------- ------------- ------------- -------------
Operating income ...................................... 104,846 125,442 419,603 387,939
Other income (expense):
Interest income .......................................... 4,138 3,765 16,355 16,531
Interest expense ......................................... (6,464) (6,685) (29,439) (24,836)
Other, net ............................................... (239) 288 (5,704) 4,630
------------- ------------- ------------- -------------
Income from continuing operations before
taxes, minority interest and equity in
earnings (losses) of affiliates ...................... 102,281 122,810 400,815 384,264
Income taxes ................................................. (32,832) (40,237) (132,924) (130,603)
Minority interest in net income of subsidiaries .............. (6,258) (6,438) (21,917) (17,442)
Equity in earnings (losses) of affiliates .................... 1,017 614 5,037 (73)
------------- ------------- ------------- -------------
Income from continuing operations ............................ 64,208 76,749 251,011 236,146
Discontinued operations:
Income (loss) from operations of discontinued
components (including write-down of long-
lived assets of $8.5 million in 2008 and a
write-down of long-lived assets of $32.7
million and a net gain on sale of discontinued
operations of $1.1 million in 2007) .................... (11,186) 2,315 (12,146) (33,441)
Income tax benefit (expense) ............................. 3,889 (795) 4,278 12,468
------------- ------------- ------------- -------------
Income (loss) from discontinued operations ............... (7,297) 1,520 (7,868) (20,973)
------------- ------------- ------------- -------------
Net income ................................................... $ 56,911 $ 78,269 $ 243,143 $ 215,173
============= ============= ============= =============
Earnings from continuing operations per share:
Basic .................................................... $ 0.72 $ 0.86 $ 2.82 $ 2.67
============= ============= ============= =============
Diluted .................................................. $ 0.72 $ 0.83 $ 2.75 $ 2.59
============= ============= ============= =============
Income (loss) from discontinued operations per share:
Basic .................................................... $ (0.08) $ 0.02 $ (0.09) $ (0.24)
============= ============= ============= =============
Diluted .................................................. $ (0.08) $ 0.02 $ (0.08) $ (0.23)
============= ============= ============= =============
Earnings per share:
Basic .................................................... $ 0.64 $ 0.88 $ 2.73 $ 2.43
============= ============= ============= =============
Diluted .................................................. $ 0.64 $ 0.85 $ 2.67 $ 2.36
============= ============= ============= =============
Weighted-average common shares outstanding:
Basic .................................................... 88,673 89,082 89,080 88,559
============= ============= ============= =============
Diluted .................................................. 89,405 92,031 91,221 91,163
============= ============= ============= =============
Note: The above prior period amounts have been adjusted to reflect the effects
of our discontinued operations.
6
- more -
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
December 27, December 29,
2008 2007
------------- -------------
ASSETS
Current assets:
Cash and cash equivalents .................................................. $ 369,570 $ 247,590
Available-for-sale securities............................................... -- 997
Accounts receivable, net of reserves of $42,855 and $41,315 ................ 734,027 708,307
Inventories, net ........................................................... 731,654 666,786
Deferred income taxes ...................................................... 36,974 32,827
Prepaid expenses and other ................................................. 194,047 192,292
------------- -------------
Total current assets ............................................... 2,066,272 1,848,799
Property and equipment, net .................................................... 247,835 247,671
Goodwill ....................................................................... 922,952 917,194
Other intangibles, net ......................................................... 214,093 192,420
Investments and other .......................................................... 148,482 107,900
------------- -------------
Total assets ....................................................... $ 3,599,634 $ 3,313,984
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ........................................................... $ 554,773 $ 474,009
Bank credit lines .......................................................... 4,936 8,977
Current maturities of long-term debt ....................................... 156,405 24,319
Accrued expenses:
Payroll and related ..................................................... 135,523 136,291
Taxes ................................................................... 69,792 73,278
Other ................................................................... 262,236 223,765
------------- -------------
Total current liabilities .......................................... 1,183,665 940,639
Long-term debt ................................................................. 266,646 423,274
Deferred income taxes ........................................................... 91,249 80,260
Other liabilities .............................................................. 58,109 53,906
Minority interest .............................................................. 67,780 35,923
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized,
none outstanding ........................................................ -- --
Common stock, $.01 par value, 240,000,000 shares authorized,
89,351,849 outstanding on December 27, 2008 and
89,603,660 outstanding on December 29, 2007 ............................. 894 896
Additional paid-in capital .................................................. 705,799 673,763
Retained earnings ........................................................... 1,195,771 1,005,055
Accumulated other comprehensive income ...................................... 29,721 100,268
------------- -------------
Total stockholders' equity ......................................... 1,932,185 1,779,982
------------- -------------
Total liabilities and stockholders' equity ......................... $ 3,599,634 $ 3,313,984
============= =============
7
- more -
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Three Months Ended
-----------------------------
December 27, December 29,
2008 2007
------------- -------------
(unaudited) (unaudited)
Cash flows from operating activities:
Net income ................................................................. $ 56,911 $ 78,269
Adjustments to reconcile net income to net cash
provided by operating activities:
Gain on sale of discontinued operation, net of tax .................. -- (1,602)
Impairment from write-down of long-lived assets of
discontinued operations ....................................... 8,484 --
Depreciation and amortization ....................................... 18,944 20,915
Stock-based compensation expense .................................... 2,369 5,833
Provision for losses on trade and other accounts receivable ......... 2,544 322
Provision for (benefit from) deferred income taxes .................. (2,792) 9,326
Stock issued to 401(k) plan ......................................... -- --
Undistributed (earnings) losses of affiliates ....................... (1,017) (614)
Minority interest in net income of subsidiaries ..................... 6,258 6,438
Other ............................................................... 2,282 (3,642)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... 39,917 60,557
Inventories ................................................... (178) 15,995
Other current assets .......................................... 14,710 (48,353)
Accounts payable and accrued expenses ......................... 47,653 (23,158)
------------- -------------
Net cash provided by operating activities ...................................... 196,085 120,286
------------- -------------
Cash flows from investing activities:
Purchases of fixed assets ................................................. (12,751) (23,798)
Payments for equity investment and business acquisitions,
net of cash acquired ................................................... (102,540) (81,884)
Cash received from business divestitures .................................. -- 10,766
Purchases of available-for-sale securities ................................ -- --
Proceeds from sales of available-for-sale securities ...................... 4,150 27,750
Net proceeds from (payments for) foreign exchange forward
contract settlements ................................................... 32,246 (15,261)
Other ..................................................................... (3,377) 408
------------- -------------
Net cash used in investing activities .......................................... (82,272) (82,019)
------------- -------------
Cash flows from financing activities:
Proceeds from issuance of long-term debt .................................. -- --
Proceeds from (repayments of) bank borrowings ............................. (1,411) 5,766
Principal payments for long-term debt ..................................... (3,582) (5,374)
Proceeds from issuance of stock upon exercise of stock options ............ 608 2,740
Payments for repurchases of common stock .................................. (27,843) --
Excess tax benefits related to stock-based compensation ................... 406 1,071
Other ..................................................................... 902 (471)
------------- -------------
Net cash provided by (used in) financing activities ............................ (30,920) 3,732
------------- -------------
Net change in cash and cash equivalents ........................................ 82,893 41,999
Effect of exchange rate changes on cash and cash equivalents ................... (1,687) (1,867)
Cash and cash equivalents, beginning of period ................................. 288,364 207,458
------------- -------------
Cash and cash equivalents, end of period ....................................... $ 369,570 $ 247,590
============= =============
Years Ended
-----------------------------
December 27, December 29,
2008 2007
------------- -------------
Cash flows from operating activities:
Net income ................................................................. $ 243,143 $ 215,173
Adjustments to reconcile net income to net cash
provided by operating activities:
Gain on sale of discontinued operation, net of tax .................. -- (673)
Impairment from write-down of long-lived assets of
discontinued operations ....................................... 8,484 32,667
Depreciation and amortization ....................................... 78,127 73,936
Stock-based compensation expense .................................... 25,429 22,553
Provision for losses on trade and other accounts receivable ......... 6,255 1,384
Provision for (benefit from) deferred income taxes .................. (4,083) (7,404)
Stock issued to 401(k) plan ......................................... 4,662 4,104
Undistributed (earnings) losses of affiliates ....................... (5,037) 73
Minority interest in net income of subsidiaries ..................... 21,917 17,442
Other ............................................................... 150 (6,512)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (26,834) (21,964)
Inventories ................................................... (68,360) (15,946)
Other current assets .......................................... 11,216 (58,194)
Accounts payable and accrued expenses ......................... 89,580 13,572
------------- -------------
Net cash provided by operating activities ...................................... 384,649 270,211
------------- -------------
Cash flows from investing activities:
Purchases of fixed assets ................................................. (50,870) (56,821)
Payments for equity investment and business acquisitions,
net of cash acquired ................................................... (128,470) (206,182)
Cash received from business divestitures .................................. -- 15,827
Purchases of available-for-sale securities ................................ (35,925) (115,066)
Proceeds from sales of available-for-sale securities ...................... 5,722 163,065
Net proceeds from (payments for) foreign exchange forward
contract settlements ................................................... 41,336 (32,241)
Other ..................................................................... 330 (10,629)
------------- -------------
Net cash used in investing activities .......................................... (167,877) (242,047)
------------- -------------
Cash flows from financing activities:
Proceeds from issuance of long-term debt .................................. -- 483
Proceeds from (repayments of) bank borrowings ............................. (7,197) 1,212
Principal payments for long-term debt ..................................... (33,721) (47,903)
Proceeds from issuance of stock upon exercise of stock options ............ 25,649 35,459
Payments for repurchases of common stock .................................. (82,788) (30,689)
Excess tax benefits related to stock-based compensation ................... 11,041 12,668
Other ..................................................................... (954) (2,350)
------------- -------------
Net cash provided by (used in) financing activities ............................ (87,970) (31,120)
------------- -------------
Net change in cash and cash equivalents ........................................ 128,802 (2,956)
Effect of exchange rate changes on cash and cash equivalents ................... (6,822) 1,899
Cash and cash equivalents, beginning of period ................................. 247,590 248,647
------------- -------------
Cash and cash equivalents, end of period ....................................... $ 369,570 $ 247,590
============= =============
8
- more -
Exhibit A
Henry Schein, Inc.
2008 Fourth Quarter
Sales Growth Rate Summary
(unaudited)
Q4 2008 over Q4 2007
--------------------
Consolidated Dental Medical International Technology
------------ ----------- ------------ ------------- ------------
Internal Sales Growth -3.0% -0.3% -13.5% 0.1% 10.9%
Acquisitions 1.2% 0.0% 0.9% 2.8% 0.0%
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth -1.8% -0.3% -12.6% 2.9% 10.9%
Foreign Currency Exchange -5.7% -2.1% 0.0% -13.7% -4.4%
------------ ----------- ------------ ------------- ------------
Total Sales Growth -7.5% -2.4% -12.6% -10.8% 6.5%
============ =========== ============ ============= ============
Q4 YTD 2008 over Q4 YTD 2007
----------------------------
Consolidated Dental Medical International Technology
------------ ----------- ------------ ------------- ------------
Internal Sales Growth 1.3% 4.0% -7.8% 4.9% 8.7%
Acquisitions 6.2% 0.8% 0.6% 17.9% 16.6%
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 7.5% 4.8% -7.2% 22.8% 25.3%
Foreign Currency Exchange 0.8% 0.0% 0.0% 2.7% -1.5%
------------ ----------- ------------ ------------- ------------
Total Sales Growth 8.3% 4.8% -7.2% 25.5% 23.8%
============ =========== ============ ============= ============
9
- more -
Exhibit B
Henry Schein, Inc.
2008 Fourth Quarter and Full Year
Reconciliation of GAAP results of
continuing operations to non-GAAP results
of continuing operations
(in thousands, except per share data)
(unaudited)
Fourth Quarter % Full Year %
2008 2007 Growth 2008 2007 Growth
From Continuing Operations
- ------------------------------------------------------------------------------------------------------------------------------------
Net Sales $1,584,653 $1,712,836 -7.5% $6,394,874 $5,904,416 8.3%
Operating Income 104,846 125,442 -16.4% 419,603 387,939 8.2%
Margin 6.6% 7.3% -71 bp 6.6% 6.6% -1 bp
Income from Continuing Operations $ 64,208 $ 76,749 -16.3% $ 251,011 $ 236,146 6.3%
Diluted EPS from Continuing Operations 0.72 0.83 -13.3% 2.75 2.59 6.2%
Net Income 56,911 78,269 -27.3% 243,143 215,173 13.0%
Diluted EPS 0.64 0.85 -24.7% 2.67 2.36 13.1%
- ------------------------------------------------------------------------------------------------------------------------------------
Subtract: Non-GAAP Adjustments
Net Sales -- -- -- --
Operating Income $ 23,240 -- $ 23,240 --
Income from Continuing Operations 15,991 -- 19,036 --
Diluted EPS from Continuing Operations 0.18 -- 0.21 --
Net Income 15,991 -- 19,036 --
Diluted EPS 0.18 -- 0.21 --
Adjusted Results
- ------------------------------------------------------------------------------------------------------------------------------------
Net Sales $1,584,653 $1,712,836 -7.5% $6,394,874 $5,904,416 8.3%
Operating Income 128,086 125,442 2.1% 442,843 387,939 14.2%
Margin 8.1% 7.3% 76 bp 6.9% 6.6% 35 bp
Income from Continuing Operations $ 80,199 $ 76,749 4.5% $ 270,047 $ 236,146 14.4%
Diluted EPS from Continuing Operations 0.90 0.83 8.4% 2.96 2.59 14.3%
Net Income 72,902 78,269 -6.9% 262,179 215,173 21.8%
Diluted EPS 0.82 0.85 -3.5% 2.87 2.36 21.6%
- ------------------------------------------------------------------------------------------------------------------------------------
Note:
Above reflects adjusted results from continuing operations excluding
restructuring costs of $23,240 ($15,991 after tax) recorded in the fourth
quarter and losses of $4,511 ($3,045 after tax) related to the Lehman Brothers
bankruptcy recorded in the third quarter. This non-GAAP comparison is being
presented in order to provide a more comparable basis for analysis.
CONTACTS: Investors: Steven Paladino
Executive Vice President and Chief Financial Officer
steven.paladino@henryschein.com
(631) 843-5500
Media: Susan Vassallo
Vice President, Corporate Communications
susan.vassallo@henryschein.com
(631) 843-5562
10
###